Product-Specific Recommendations for Generic Drug Development

To successfully develop and manufacture a generic drug product, an applicant should consider that their  product is expected to be:  pharmaceutically equivalent to its reference listed drug (RLD), i.e., to have the same active ingredient, dosage form, strength, and route of administration under the same conditions of use,  bioequivalent to the RLD, i.e., to show no significant difference in the rate and extent of absorption of the active pharmaceutical ingredient;  and, consequently,  therapeutically equivalent, i.e., to be substitutable for the RLD with the expectation that the generic product will have the same safety and efficacy as its reference listed drug. 

According 21 CFR 320.24, different types of evidence may be used to establish bioequivalence for pharmaceutically equivalent drug products, including in vivo or in vitro testing, or both. The selection of the method used to demonstrate bioequivalence depends upon the purpose of the study, the analytical methods available, and the nature of the drug product.  Under this regulation, applicants must conduct bioequivalence testing using the most accurate, sensitive, and reproducible approach available among those set forth in 21 CFR 320.24.  As the initial step for selecting methodology for generic drug product development, applicants are referred to the following draft guidance: Draft Guidance for Industry on Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application (ANDA) (Dec. 2013).

To further facilitate generic drug product availability and to assist generic pharmaceutical industry with identifying the most appropriate methodology for developing drugs and generating evidence needed to support ANDA approval, FDA publishes product-specific recommendations describing  the Agency’s current thinking and expectations on how to develop generic drug products therapeutically equivalent to specific reference-listed drugs.  

These recommendations are published in an incremental manner and listed below in alphabetical order according to RLD’s name. The most recently published recommendations (new and revised) are listed below.

The Agency is seeking feedback and considers comments to the docket on these recommendations. The comments should be submitted to the Division of Dockets Management (DDM) under Docket FDA-2007-D-0369-0015. For electronic comments, refer to the website http://www.regulations.gov OR mail your written comments to DDM (HFA-305), FDA, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Please contact the Regulations.gov Help Desk at 1-877-378-5457 (toll free) for assistance regarding submissions.

For additional information on development of generic drug products refer to Biopharmaceutics  

Bioequivalence Recommendations for Specific Products Arranged by Active Ingredient [Total count 1456]
A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Newly Added Recommendations since June 1, 2016 (20 New; 21Revisions) updated 8/29/2016

Active Ingredient
(link to Specific Guidance)
TypeRoute of AdministrationDosage FormRLD Application Number
(link to Orange Book)
Date Recommended

 Amcinonide (PDF -38KB) 

 DraftTopical Lotion763296/2016

 Cariprazine HCl (PDF - 40KB)

 Draft Oral



 Cobimetinib fumarate (PDF -58KB)


 Empagliflozin and Metformin HCl (PDF - 41KB) 


 Erythromycin ethylsuccinate (PDF - 39KB)


 Everolimus (PDF - 178KB)


Fidaxomicin (PDF -26KB) the word new in a red box

 Flibanserin (PDF - 41KB)DraftOralTablet225266/2016

 Fluocinonide (PDF -38KB)


Fluocinonide (PDF - 38KB)

Draft TopicalOintment0750086/2016

Hydrocortisone (PDF - 35KB)


 Lesinurad (PDF -38KB)


 Meloxicam (PDF - 40KB)


Methylergonovine maleate (PDF -39KB)




 Ombitasvir; Paritaprevir; Ritonavir (PDF - 40KB)


 Prednicarbate (PDF - 38KB)


 Propofol (PDF - 63KB)


 Pseudoephedrine HCl (PDF - 40KB

DraftOralTablet, Extended Release0735856/2016

 Selexipag (PDF - 42KB)


 Tacrolimus (PDF - 49KB)

DraftOralTablet, Extended Release2064066/2016


Newly Revised Bioequivalence Recommendations since June 1, 2016

Active Ingredient
(link to Specific Guidance)
TypeRoute of AdministrationDosage FormRLD Application Number
(link to Orange Book)
Date Recommended
Acetaminophen; Hydrocodone Bitartrate (PDF - 17 KB) RevisedDraftOralTablet







Albuterol Sulfate (PDF - 15 KB) RevisedDraftOralTablet728946/2016

 Azelastine HCl and fluticasone propionate (PDF - 78KB) Revised

DraftNasalSpray, metered2022366/2016
Benzoyl Peroxide; Clindamycin Phosphate (PDF - 257KB)   RevisedDraftTopicalGel508196/2016
Dexamethasone; Tobramycin (PDF - 64KB) RevisedDraft OphthalmicOintment50616 6/2016
Dexamethasone; Tobramycin (PDF-49KB)RevisedDraftOphthalmicSuspension508186/2016
Dexamethasone;Tobramycin (PDF - 35 KB) RevisedDraftOphthalmicSuspension505926/2016
Lansoprazole (PDF - 16KB)
DraftOralTablet, Delayed-Release, Orally Disintegrating214286/2016
Loteprednol Etabonate; Tobramycin (PDF - 70KB)Revised DraftOphthalmicSuspension508046/2016
Loteprednol Etabonate (PDF - 58KB)RevisedDraftOphthalmicDrops, suspension


Mesalamine (PDF - 44KB) RevisedDraftOralCapsule, Delayed Release2044126/2016
Mesalamine (PDF - 67KB) RevisedDraft OralTablet, Delayed Release218306/2016
Mesalamine (PDF - 66KB) RevisedDraft OralTablet, Delayed Release220006/2016

Methylphenidate (PDF - 266KB) Revised

DraftTransdermalFilm, Extended Release215146/2016
Morphine Sulfate (PDF - 23KB)
DraftOralCapsule, Extended Release206166/2016
Paliperidone Palmitate (PDF - 35KB) RevisedDraftInjection, IntramuscularSuspension, Extended Release222647/2016
Paroxetine (PDF - 18KB) RevisedDraftOralTablet, Extended Release209366/2016

Pomalidomide (PDF - 24KB) Revised

Prednisolone Acetate (PDF - 69KB) RevisedDraftOphthalmicSuspension/Drops170116/2016
Rimexolone (PDF - 21KB) RevisedDraftOphthalmicDrops, Suspension0204746/2016
Risperidone (PDF - 47KB) RevisedDraftIntramuscularInjection213468/2016



Page Last Updated: 08/29/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.